Latest News


June 03, 2020

Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease

February 07, 2020

Complexa Names Elisabeth Leiderman, MD, MBA, Chief Business Officer

October 04, 2019

Complexa Receives Orphan Drug Designation from the FDA for CXA-10 in Pulmonary Arterial Hypertension

August 18, 2019

Complexa Names Theodore Danoff, MD, PhD, Chief Medical Officer

February 21, 2019

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension

September 24, 2018

Complexa Presents Data Evaluating the Pharmacological Action of CXA-10 on Drug-metabolizing Transport Proteins at 2018 American College of Clinical Pharmacology Annual Meeting

July 26, 2018

Complexa Names William Leong, Vice President of Chemistry, Manufacturing and Controls

June 28, 2018

Complexa Announces Presentation of Phase 1 Data Evaluating Lead Candidate CXA-10 as a Disease-Modifying Therapy in Pulmonary Arterial Hypertension at PHA’s 2018 International PH Conference

June 01, 2018

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis

Please reload